[["Subclinical hypothyroidism (SH)", "is defined by", "elevated serum levels of thyroid stimulating hormone (TSH) with normal levels of free thyroid hormones"], ["Subclinical hypothyroidism (SH)", "is common in", "adults, especially in women over 60 years of age"], ["up to two-thirds of individuals with SH", "have", "serum TSH levels between 5-10 mU/L and thyroid autoantibodies"], ["almost half of individuals with SH", "may progress to", "overt thyroid failure"], ["annual percent risk of progression", "increases with", "serum TSH level"], ["elevated TSH levels in SH patients", "do not reflect", "pituitary compensation to maintain euthyroidism"], ["elevated TSH levels in SH patients", "indicate", "mild tissue hypothyroidism sensu strictu"], ["lasting SH more than 6-12 months", "may be associated with", "an atherogenic lipid profile"], ["lasting SH more than 6-12 months", "may be associated with", "a hypercoagulable state"], ["lasting SH more than 6-12 months", "may be associated with", "a subtle cardiac defect with mainly diastolic dysfunction"], ["lasting SH more than 6-12 months", "may be associated with", "impaired vascular function"], ["lasting SH more than 6-12 months", "may be associated with", "reduced submaximal exercise capacity"], ["deviation from normality", "increases with", "serum TSH level"], ["restoration of euthyroidism by levothyroxine (LT4) treatment", "may correct", "the lipid profile and cardiac abnormalities"], ["strong association between SH and atherosclerotic cardiovascular disease", "has been reported in", "the Rotterdam Study"], ["whether SH confers a high risk for cardiovascular disease", "remains", "a topic of controversy"], ["whether LT4 therapy has a long-term benefit", "remains", "a topic of controversy"], ["LT4 therapy", "should be prescribed", "on a case-by-case basis"], ["LT4 therapy prescription", "takes into account", "the risk of progressive thyroid failure"], ["LT4 therapy prescription", "takes into account", "the risk of cardiovascular events"]]